Christian Ruff, MD

home / authors / christian-ruff-md

Dr Ruff is the director of general cardiology at Bringham and Women's Hospital, and also an associate professor at Harvard Medical School.

Articles

April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

March 30th 2025

Abelacimab Shows Unprecedented Bleeding Risk Reduction in Patients With Atrial Fibrillation

Giuliana Grossi Christian Ruff, MD

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.

February 11th 2025

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

February 6th 2025

Dr Ruff Explores Mitigating Surgical Bleeding in AFib With Abelacimab

Kyle Munz Christian Ruff, MD

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com

January 22nd 2025

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).